Skip to main content
. Author manuscript; available in PMC: 2014 Sep 26.
Published in final edited form as: J Med Chem. 2013 Sep 4;56(18):7212–7221. doi: 10.1021/jm400474r

Figure 1.

Figure 1

Figure 1

Identification of Cryptotanshinone as an inhibitor of SHP2. (A) Chemical structure of Cryptotanshinone. (B) Phosphatase assays were carried out using the indicated phosphatases as enzymes and a phospho-EGFR peptide as the substrate in the presence of various concentrations of Cryptotanshinone, as described in Experimental Section. For IC50 determinations, 6 concentrations of Cryptotanshinone were tested. Results shown are mean±S.E.M. of three independent experiments. (C) PTP activities of the SHP2 PTP domain, WT full length SHP2, and full length SHP2 E76K were determined in the presence of Cryptotanshinone at the indicated concentrations using a phospho-EGFR peptide as the substrate. Experiments were repeated three times. Similar results were obtained in each. Results shown are mean±S.E.M. of triplicates from one experiment. Shown on the right panel are purified recombinant proteins stained with Coomassie blue.